Dup15q Syndrome Market: Insights into Epidemiology, Treatments, and Key Companies | Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix

Dup15q syndrome is a neurogenetic condition caused by duplications on chromosome 15q11.2-13.1. It is marked by hypotonia, developmental delays, intellectual disability (ID), epilepsy, and autism spectrum disorder (ASD). The extent of developmental impairments can vary significantly based on the nature of the duplication and whether it originated from the mother or father.

Emerging therapies for Dup15q syndrome, including Bexicaserin, UBE3A (ASO), and others, are anticipated to drive growth in the Dup15q syndrome market over the coming years.

DelveInsight has released a new report titled "Dup15q Syndrome - Market Insights, Epidemiology, and Market Forecast-2034", providing a comprehensive analysis of the disorder, with historical and projected epidemiology as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Dup15q syndrome market report @ https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Dup15q syndrome Market Report:

*
In March 2025, Quiver Bioscience entered into a partnership with the Dup15q Alliance to advance an antisense oligonucleotide (ASO) therapy aimed at reducing UBE3A gene overexpression, a central factor in Dup15q syndrome. This collaboration leverages Quiver's Genomic Positioning System, which integrates AI with human neuronal models to accelerate drug discovery. The ASO program remains in the preclinical stage.

*
In 2024, the FDA recalled certain batches of Clonazepam Orally Disintegrating Tablets due to possible mislabeling of product strength. Overall, therapeutic development for Dup15q syndrome remains limited, with only a few candidates under clinical investigation. These include bexacaserin (Lundbeck) for Developmental and Epileptic Encephalopathies (DEEs). Meanwhile, Roche has withdrawn basmisanil (RG1662) from its Dup15q program, raising uncertainty about future progress. Similarly, Takeda discontinued development of soticlestat in January 2025 following negative trial outcomes in Dravet and Lennox-Gastaut syndromes.

*
While some companies like Quiver remain in early preclinical phases, others are pursuing indirect opportunities. For instance, Acadia Pharmaceuticals and Saniona are advancing SAN2465, initially developed for major depressive disorder, into Phase II trials, with potential applicability for neuropsychiatric symptoms in Dup15q syndrome.

*
Despite ongoing hurdles, the outlook is gradually improving through scientific innovation, collaborative partnerships, and strong patient advocacy, which are collectively driving momentum toward potential disease-modifying therapies.

*
Chromosome 15q11.2-13.1 duplication syndrome (Dup15q syndrome) is a rare genetic disorder caused by duplication of a segment on the long arm of chromosome 15, specifically 15q11.2-13.1. This duplication typically occurs as either an extra isodicentric chromosome 15 [idic(15)] or an interstitial duplication [int dup(15)]. This region, often called the Prader-Willi/Angelman critical region (PWACR), is also implicated in both Prader-Willi and Angelman syndromes.

*
Clinical features of Dup15q syndrome commonly include hypotonia (low muscle tone), motor development delays, intellectual disability of varying severity, autism spectrum disorder (ASD), and epilepsy, including infantile spasms. Symptom severity differs between individuals and is influenced by factors such as the number of duplicated copies and whether the duplication originated maternally or paternally.

*
Key players in the Dup15q syndrome market include Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, and Zogenix, among others. Emerging therapies such as Bexicaserin, UBE3A (ASO), and additional candidates are expected to shape the future treatment landscape.

Dup15q syndrome Overview

Dup15q syndrome (Chromosome 15q11.2-13.1 duplication syndrome) is a rare genetic disorder caused by the duplication of a segment on the long arm of chromosome 15, specifically the 15q11.2-13.1 region. This duplicated segment can occur in two main forms:

*
Isodicentric chromosome 15 [idic(15)] - an extra chromosome containing two copies of the 15q11.2-13.1 region.

*
Interstitial duplication [int dup(15)] - an extra copy of the region within the same chromosome.

This region is also known as the Prader-Willi/Angelman critical region (PWACR) because of its role in both Prader-Willi and Angelman syndromes.

Dup15q syndrome Market Outlook

Supportive care for Dup15q syndrome is tailored to each individual's specific needs. Physical and occupational therapies address delays in motor skills, while communication difficulties are managed with augmentative and alternative communication (AAC) tools. Behavioral challenges, particularly those associated with autism, are often treated using approaches such as applied behavior analysis (ABA), and psychotropic medications may be prescribed for more severe behavioral issues. Seizures are managed through conventional anticonvulsants, ketogenic diets, or vagus nerve stimulation to reduce their frequency and intensity.

Therapeutic development for Dup15q syndrome remains limited, with only a few candidates in the pipeline. Bexacaserin by Lundbeck is being investigated for developmental and epileptic encephalopathies (DEEs) but is not specific to Dup15q. SAN2465 from Saniona, originally developed for major depressive disorder, shows potential for addressing neuropsychiatric symptoms in Dup15q. Additionally, Quiver Bioscience is developing a preclinical antisense oligonucleotide (ASO) therapy aimed at lowering UBE3A gene expression, which could help alleviate symptom severity.

Discover how the Dup15q syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Dup15q syndrome Emerging Drugs

*
Bexicaserin: Lundbeck

*
UBE3A (ASO): Quiver Bioscience

Scope of the Dup15q syndrome Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Dup15q syndrome Companies: Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix, and others

*
Key Dup15q syndrome Therapies: Bexicaserin, UBE3A (ASO), and others

*
Dup15q syndrome Therapeutic Assessment: Dup15q syndrome current marketed and Dup15q syndrome emerging therapies

*
Dup15q syndrome Market Dynamics: Dup15q syndrome market drivers and Dup15q syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Dup15q syndrome Unmet Needs, KOL's views, Analyst's views, Dup15q syndrome Market Access and Reimbursement

To know what's more in our Dup15q syndrome report, visit https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Dup15q syndrome Market Report:

*
Dup15q syndrome market report covers a descriptive overview and comprehensive insight of the Dup15q syndrome Epidemiology and Dup15q syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Dup15q syndrome market report provides insights into the current and emerging therapies.

*
The Dup15q syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Dup15q syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dup15q syndrome market.

Got queries? Click here to know more about the Dup15q syndrome market Landscape [https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Dup15q syndrome Patient Share (%) Overview at a Glance

5. Dup15q syndrome Market Overview at a Glance

6. Dup15q syndrome Disease Background and Overview

7. Dup15q syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Dup15q syndrome

9. Dup15q syndrome Current Treatment and Medical Practices

10. Unmet Needs

11. Dup15q syndrome Emerging Therapies

12. Dup15q syndrome Market Outlook

13. Country-Wise Dup15q syndrome Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Dup15q syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Dup15q syndrome Market Outlook 2034 [https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Dup15q syndrome Pipeline Insights, DelveInsight

"Dup15q syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dup15q syndrome market. A detailed picture of the Dup15q syndrome pipeline landscape is provided, which includes the disease overview and Dup15q syndrome treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dup15q-syndrome-market-insights-into-epidemiology-treatments-and-key-companies-ovid-therapeutics-takeda-qstate-biosciences-radius-health-zogenix]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.